dr. andreadis on antibody-drug conjugates in dlbcl
Published 4 years ago • 134 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
0:57
dr. andreadis on the treatment of relapsed dlbcl
-
1:01
dr. andreadis discusses the role of ibrutinib in dlbcl
-
1:42
dr. andreadis discusses fda-approved car t-cell therapies in dlbcl
-
1:41
dr. andreadis on the current state of car t-cell therapy in lymphoma
-
5:59
use of antibody drug conjugates and potential for ild
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
29:11
t-cell immune pathology in the brain in asd – m. anderson md, harvard medical school @synchrony2020
-
11:49
how do monoclonal antibodies work? rituximab, infliximab, adalimumab and others
-
8:12
role of antibody drug conjugates and personal experience
-
2:39
dr. diefenbach explains antibody drug conjugates
-
1:38
dr. hart on antibody-drug conjugates in her2 breast cancer
-
8:18
antibody drug conjugates and interstitial lung disease risk
-
0:57
dr. cobleigh on antibody-drug conjugates in development in her2 breast cancer
-
6:24
introduction: antibody-drug conjugates in lymphoma
-
0:53
dr. andreadis on treatment approaches in relapsed mcl
-
16:32
new antibodies and antibody-drug conjugates for b-cell lymphoma
-
6:20
antibody-drug conjugates for tnbc
-
1:04
dr. isaacs discusses antibody drug conjugates in tnbc
-
3:23
antibody-drug conjugates in the treatment of solid tumors
-
0:55
dr. andreadis on response to car t-cell therapy
-
1:09
dr. hill on the impact of recent approvals in relapsed/refractory dlbcl
-
4:59
novel antibody drug conjugates in development for lymphoid malignancies